Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
0
--
--
0
0
0
Croissance des revenus (H/H)
--
--
--
--
--
--
Coût des ventes
--
--
--
--
--
0
Bénéfice brut
--
--
--
--
--
0
Vente, Général et Administration
2
--
--
0
0
1
Recherche et développement
0
--
--
0
0
0
Frais d'exploitation
2
--
--
1
0
2
Autres revenus (charges) non opérationnels
--
--
--
0
--
--
Bénéfice avant impôts
-3
--
--
-1
-1
-3
Charge d'impôt sur le revenu
--
--
--
0
0
0
Bénéfice net
-3
--
--
-1
-1
-3
Croissance du bénéfice net
200%
--
--
0%
-67%
0%
Actions en circulation (diluées)
572.13
--
--
521.78
507.95
455.68
Variation des actions (H-H)
7%
--
--
3%
11%
15%
EPS (dilué)
0
--
--
0
0
0
Croissance du EPS
120%
--
--
-18%
-59%
-8%
Flux de trésorerie libre
-1
0
0
0
0
0
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
--
--
--
--
--
0%
Marge opérationnelle
0%
--
--
0%
0%
0%
Marge bénéficiaire
0%
--
--
0%
0%
0%
Marge du flux de trésorerie libre
0%
--
--
0%
0%
0%
EBITDA
-2
--
--
-1
0
-2
Marge EBITDA
0%
--
--
0%
0%
0%
D&A pour le résultat opérationnel
0
0
0
0
0
0
EBIT
-2
--
--
-1
0
-2
Marge EBIT
0%
--
--
0%
0%
0%
Taux d'imposition effectif
--
--
--
0%
0%
0%
Follow-Up Questions
Preveceutical Medical Inc의 주요 재무제표는 무엇인가요?
PRVCF의 주요 재무 비율은 무엇인가요?
Preveceutical Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Preveceutical Medical Inc은 수익성이 있나요?
Preveceutical Medical Inc에 부채가 있나요?
Preveceutical Medical Inc의 발행 주식은 몇 주인가요?
Statistiques clés
Clôture préc.
$0.0172
Prix d'ouverture
$0.0179
Plage de la journée
$0.0172 - $0.0179
Plage de 52 semaines
$0.0037 - $0.0436
Volume
15.0K
Volume moyen
58.9K
BPA (TTM)
0.00
Rendement en dividend
--
Capitalisation boursière
$10.2M
Qu’est-ce que PRVCF ?
Preveceutical Medical Inc is a CA-based company operating in industry. The company is headquartered in West Vancouver, British Columbia. The company went IPO on 2016-12-30. PreveCeutical Medical Inc. is a Canada-based health sciences company. The Company’s principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Company’s pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, and BSV Peptide Program. Its Cannabinoid Sol-Gel is a cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). Its Nature Identical peptides used for treatment of various ailments. Its Dual Gene Therapy for curative and prevention therapies for diabetes and obesity.